The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
| Tony Truong, MD, MPH | |
| 403-955-7272 | |
| [email protected] |
| Greg Guilcher, MD | |
| 403-955-7272 | |
1 Year - 19 Years
Phase 2
Interventional
All
Drug
Radiation
Patients must be ≥ 12 months and < 19 years of age at the time of study enrollment.
Patients must have sickle cell disease as defined by hemoglobin electropheresis, as follows:
homozygous Hb S disease (HbSS),
sickle-Hb C disease (HbSC),
sickle beta-plus-thalassemia (HbS/β+), or
sickle beta-null-thalassemia (HbS/βo)
Patients must meet standard eligibility criteria to undergo HSCT, including but not limited to one or more of the following:
history of repeated (more than 1) bony (vaso-occlusive) crisis
history of stroke
elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy)
history of acute chest crisis or splenic sequestration crisis
history of priapism in males
history of osteonecrosis
pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) > 2.5 m/s on echocardiogram
red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy
Sickle complications should be present despite the use of hydroxyurea, but this is not an absolute requirement, if the treating team considers the patient to be at high risk for further crisis episodes.
Patients who are unable to comply with or follow the study protocol.
Patients with known hypersensitivity to sirolimus, its derivatives or to any of its components.